USD 0.6255
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| AIMD | -3.8 | -9.3 | 38.7 | 13.7 | -16.6 | -47.9 | -98.8 | -97.2 | -97.9 | -92.7 |
| S&P 500 | 1.0 | 1.5 | 1.1 | 2.3 | 8.9 | 23.6 | 33.8 | 80.6 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | AIMD |
| name | Ainos, Inc. |
| price | 0.6255 |
| changes percentage | -3.7692 |
| change | -0.0245 |
| day low | 0.61 |
| day high | 0.6699 |
| year high | 3.1 |
| year low | 0.4 |
| market cap | 8810981 |
| price avg 50 | 0.49228 |
| price avg 200 | 0.6948 |
| exchange | NASDAQ |
| volume | 216950 |
| avg volume | 586218 |
| open | 0.6699 |
| previous close | 0.65 |
| eps | -2.64 |
| pe | -0.24 |
| earnings announcement | 2025-03-06T21:00:00.000+0000 |
| shares outstanding | 14086300 |
| timestamp | 2025-01-17 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001014763 | |||
| revenue | 122112 | 3519627 | -96.53 |
| gross profit | -253733 | 1405343 | -118.05 |
| gross profit ratio | -2.08 | 0.4 | -620.39 |
| research and development expenses | 7317388 | 6845964 | 6.89 |
| operating expenses | 12952663 | 15381555 | -15.79 |
| interest income | 0 | 53528 | -100.00 |
| interest expense | 144193 | 53528 | 169.38 |
| ebitda | -8773098 | -9139454 | 4.01 |
| ebitdaratio | -71.84 | -2.59 | -2672.74 |
| operating income | -13206396 | -13976212 | 5.51 |
| operating income ratio | -108.15 | -3.97 | -2623.54 |
| net income | -13770549 | -14037168 | 1.90 |
| net income ratio | -112.77 | -3.99 | -2727.55 |
| eps | -3.36 | -5.15 | 34.76 |
Revenue Growth: revenue decreased to 0 million in 2023 from 4 million in 2022 representing a change of -96.53%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 0 million in 2023 from 1 million in 2022 representing a change of -118.05%. This indicates a sales profitability decline, which is a negative sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -9 million in 2023 from -9 million in 2022 representing a change of 4.01%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -13 million in 2023 from -14 million in 2022 representing a change of 5.51%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -14 million in 2023 from -14 million in 2022 representing a change of 1.9%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Research and Development (R&D) Expenses: R&D Expenses increased to 7 million in 2023 from 7 million in 2022 representing a change of 6.89%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Expenses: Operating Expenses decreased to 13 million in 2023 from 15 million in 2022 representing a change of -15.79%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Earnings per Share (EPS): EPS increased to -3.36 in 2023 from -3.36 in 2022 representing a change of 34.76%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001014763 | |||
| revenue | 0 | 0 | NaN |
| gross profit | -547 | -25373 | 97.84 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 2022244 | 1978756 | 2.20 |
| operating expenses | 3038002 | 3023636 | 0.48 |
| interest income | 0 | 0 | NaN |
| interest expense | 264642 | 118759 | 122.84 |
| ebitda | -2222984 | -1851422 | -20.07 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -3038549 | -3049010 | 0.34 |
| operating income ratio | 0 | 0 | NaN |
| net income | -3699317 | -3195022 | -15.78 |
| net income ratio | 0 | 0 | NaN |
| eps | -0.33 | -0.49 | 32.65 |
Gross Profit: Gross Profit increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 97.84%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 2 million in 2024Q3 from 2 million in 2024Q2 representing a change of 2.2%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -2 million in 2024Q3 from -2 million in 2024Q2 representing a change of -20.07%. The increase in EBITDA indicates improved operational efficiency and profitability.
Net Income: Net income increased to -4 million in 2024Q3 from -3 million in 2024Q2 representing a change of -15.78%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.33 in 2024Q3 from -0.33 in 2024Q2 representing a change of 32.65%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 3 million in 2024Q3 from 3 million in 2024Q2 representing a change of 0.48%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Operating Income: Operating income decreased to -3 million in 2024Q3 from -3 million in 2024Q2 representing a change of 0.34%. The decrease in operating income indicates worse operational performance and decreased profitability.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001014763 | |||
| total assets | 31841804 | 37109014 | -14.19 |
| total liabilities | 7394223 | 2481008 | 198.03 |
| total equity | 24447581 | 34628006 | -29.40 |
| cash and cash equivalents | 1885628 | 1853362 | 1.74 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 2473197 | 2845917 | -13.10 |
| total non current assets | 29368607 | 34263097 | -14.29 |
| total current liabilities | 1336838 | 2472912 | -45.94 |
| total non current liabilities | 6057385 | 8096 | 74719.48 |
| common stock | 46778 | 200116 | -76.62 |
| retained earnings | -37886155 | -24115606 | -57.10 |
| total debt | 5963556 | 1268622 | 370.08 |
Total Assets: Total Assets decreased to 32 million in 2023 from 37 million in 2022 representing a change of -14.19%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 7 million in 2023 from 2 million in 2022 representing a change of 198.03%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 24 million in 2023 from 35 million in 2022 representing a change of -29.4%. This indicates a decrease in shareholders' equity.
Total Current Assets: Total Current Assets decreased to 2 million in 2023 from 3 million in 2022 representing a change of -13.1%. This indicates a worsen liquidity position.
Common Stock: Common Stock decreased to 0 in 2023 from 0 in 2022 representing a change of -76.62%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to -38 million in 2023 from -24 million in 2022 representing a change of -57.1%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 6 million in 2023 from 1 million in 2022 representing a change of 370.08%. This indicates an increase in overall debt burden.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 2 million in 2023 from 2 million in 2022 representing a change of 1.74%. This indicates an increase in available liquid assets.
Total Current Liabilities: Total Current Liabilities decreased to 1 million in 2023 from 2 million in 2022 representing a change of -45.94%. This indicates a lower short-term debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001014763 | |||
| total assets | 31369746 | 35539387 | -11.73 |
| total liabilities | 13347531 | 14827111 | -9.98 |
| total equity | 18022215 | 20712276 | -12.99 |
| cash and cash equivalents | 5156606 | 8014098 | -35.66 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 5649205 | 8471595 | -33.32 |
| total non current assets | 25720541 | 27067791 | -4.98 |
| total current liabilities | 4130771 | 5743199 | -28.08 |
| total non current liabilities | 9216760 | 9083912 | 1.46 |
| common stock | 138134 | 73887 | 86.95 |
| retained earnings | -48095304 | -44395987 | -8.33 |
| total debt | 12270000 | 13897761 | -11.71 |
Total Assets: Total Assets decreased to 31 million in 2024Q3 from 36 million in 2024Q2 representing a change of -11.73%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 18 million in 2024Q3 from 21 million in 2024Q2 representing a change of -12.99%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 5 million in 2024Q3 from 8 million in 2024Q2 representing a change of -35.66%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 6 million in 2024Q3 from 8 million in 2024Q2 representing a change of -33.32%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -48 million in 2024Q3 from -44 million in 2024Q2 representing a change of -8.33%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 13 million in 2024Q3 from 15 million in 2024Q2 representing a change of -9.98%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 4 million in 2024Q3 from 6 million in 2024Q2 representing a change of -28.08%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2024Q3 from 0 in 2024Q2 representing a change of 86.95%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 12 million in 2024Q3 from 14 million in 2024Q2 representing a change of -11.71%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001014763 | |||
| net change in cash | 32266 | 101863 | -68.32 |
| operating cash flow | -4694668 | -3021183 | -55.39 |
| free cash flow | -4787652 | -3655006 | -30.99 |
| capital expenditure | -92984 | -633823 | 85.33 |
| depreciation and amortization | 4852454 | 4833428 | 0.39 |
| deferred income tax | 0 | -16865783 | 100.00 |
| stock based compensation | 1114767 | 6421879 | -82.64 |
| accounts payables | 0 | 0 | NaN |
| inventory | 221767 | -595222 | 137.26 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -92984 | -633823 | 85.33 |
| net cash used for investing activites | -101525 | -630178 | 83.89 |
| debt repayment | 5313974 | 2070595 | 156.64 |
| common stock issued | 0 | 1780204 | -100.00 |
| common stock repurchased | -301 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 4923673 | 3831245 | 28.51 |
| cash at end of period | 1885628 | 1853362 | 1.74 |
| accounts receivables | 201091 | -201546 | 199.77 |
| cash at beginning of period | 1853362 | 1751499 | 5.82 |
Net Change in Cash: Net Change in Cash decreased to 0 million in 2023 from 0 million in 2022 representing a change of -68.32%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -5 million in 2023 from -3 million in 2022 representing a change of -55.39%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -5 million in 2023 from -4 million in 2022 representing a change of -30.99%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to 0 million in 2023 from -1 million in 2022 representing a change of 85.33%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to 0 million in 2023 from -17 million in 2022 representing a change of 100.0%. This indicates that the company's tax liability for future periods has increased.
Accounts Receivables: Accounts Receivables increased to 0 in 2023 from 0 million in 2022 representing a change of 199.77%. This suggests that the company is less capable of collecting payments from its customers.
Stock-Based Compensation: Stock-Based Compensation decreased to 1 million in 2023 from 6 million in 2022 representing a change of -82.64%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001014763 | |||
| operating cash flow | -1475144 | -1974145 | 25.28 |
| free cash flow | -1485291 | -1979993 | 24.99 |
| capital expenditure | -10147 | -5848 | -73.51 |
| depreciation and amortization | 1211691 | 1197587 | 1.18 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 470791 | 422374 | 11.46 |
| accounts receivables | 9 | 4163 | -99.78 |
| accounts payables | 0 | 0 | NaN |
| inventory | 5621 | 3333 | 68.65 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -10147 | -5848 | -73.51 |
| net cash used for investing activites | -18785 | -8512 | -120.69 |
| debt repayment | 0 | 9000000 | -100.00 |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -1481754 | 9000000 | -116.46 |
| net change in cash | -2857492 | 6983199 | -140.92 |
| cash at end of period | 5156606 | 8014098 | -35.66 |
| cash at beginning of period | 8014098 | 1030899 | 677.39 |
Net Change in Cash: Net Change in Cash decreased to -3 million in 2024Q3 from 7 million in 2024Q2 representing a change of -140.92%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Stock-Based Compensation: Stock-Based Compensation increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 11.46%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Operating Cash Flow: Operating Cash Flow increased to -1 million in 2024Q3 from -2 million in 2024Q2 representing a change of 25.28%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -1 million in 2024Q3 from -2 million in 2024Q2 representing a change of 24.99%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of -73.51%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Receivables: Accounts Receivables decreased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of -99.78%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.03 | 1.29 | -97.69 |
| net income per share | -3.36 | -5.15 | 34.71 |
| operating cash flow per share | -1.15 | -1.11 | -3.42 |
| free cash flow per share | -1.17 | -1.34 | 12.82 |
| cash per share | 0.46 | 0.68 | -32.29 |
| book value per share | 5.97 | 12.7 | -53.01 |
| tangible book value per share | -0.94 | 0.67 | -240.16 |
| shareholders equity per share | 5.97 | 12.7 | -53.01 |
| interest debt per share | 1.49 | 0.48 | 207.45 |
| market cap | 8401123.45 | 8455119.8 | -0.64 |
| enterprise value | 12479051.45 | 7870379.8 | 58.56 |
| pe ratio | -0.61 | -0.6 | -1.29 |
| price to sales ratio | 68.8 | 2.4 | 2763.89 |
| pocfratio | -1.79 | -2.8 | 36.06 |
| pfcf ratio | -1.75 | -2.31 | 24.15 |
| pb ratio | 0.34 | 0.24 | 40.74 |
| ptb ratio | 0.34 | 0.24 | 40.74 |
| ev to sales | 102.19 | 2.24 | 4470.08 |
| enterprise value over ebitda | -1.42 | -0.86 | -65.18 |
| ev to operating cash flow | -2.66 | -2.61 | -2.04 |
| ev to free cash flow | -2.61 | -2.15 | -21.05 |
| earnings yield | -1.64 | -1.66 | 1.27 |
| free cash flow yield | -0.57 | -0.43 | -31.83 |
| debt to equity | 0.24 | 0.04 | 565.83 |
| debt to assets | 0.19 | 0.03 | 447.84 |
| net debt to ebitda | -0.46 | 0.06 | -826.51 |
| current ratio | 1.85 | 1.15 | 60.76 |
| interest coverage | -91.59 | -261.1 | 64.92 |
| income quality | 0.34 | 0.22 | 58.06 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 45.66 | 0 | NaN |
| research and ddevelopement to revenue | 59.92 | 1.95 | 2980.77 |
| intangibles to total assets | 0.89 | 0.88 | 0.47 |
| capex to operating cash flow | -0.02 | -0.21 | 90.56 |
| capex to revenue | 0.76 | 0.18 | 322.84 |
| capex to depreciation | 0.02 | 0.13 | -85.39 |
| stock based compensation to revenue | 9.13 | 1.82 | 400.33 |
| graham number | 21.24 | 38.34 | -44.61 |
| roic | -0.43 | -0.39 | -10.81 |
| return on tangible assets | -3.87 | -3.26 | -18.60 |
| graham net net | -1.32 | -0.07 | -1918.27 |
| working capital | 1136359 | 373005 | 204.65 |
| tangible asset value | -3835627 | 1821268 | -310.60 |
| net current asset value | -4921026 | 364909 | -1448.56 |
| invested capital | 30296139 | 34555419 | -12.33 |
| average receivables | 101000.5 | 100773 | 0.23 |
| average payables | 0 | 0 | NaN |
| average inventory | 381407.5 | 297611 | 28.16 |
| days sales outstanding | 1.36 | 20.9 | -93.49 |
| days payables outstanding | 0 | 0 | NaN |
| days of inventory on hand | 162.76 | 102.76 | 58.39 |
| receivables turnover | 268.38 | 17.46 | 1436.83 |
| payables turnover | 0 | 0 | NaN |
| inventory turnover | 2.24 | 3.55 | -36.87 |
| roe | -0.56 | -0.41 | -38.95 |
| capex per share | 0.02 | 0.23 | -90.24 |
ROE: Return on Equity (ROE) decreased to -0.56 on 2023-12-31 from -0.41 on 2022-12-31, representing a change of -38.95%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -0.61 on 2023-12-31 from -0.60 on 2022-12-31, representing a change of -1.29%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 1.85 on 2023-12-31 from 1.15 on 2022-12-31, representing a change of 60.76%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.24 on 2023-12-31 from 0.04 on 2022-12-31, representing a change of 565.83%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| AIMD | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -0.33 | -0.49 | 33.08 |
| operating cash flow per share | -0.13 | -0.3 | 56.81 |
| free cash flow per share | -0.13 | -0.3 | 56.64 |
| cash per share | 0.46 | 1.23 | -62.81 |
| book value per share | 1.6 | 3.18 | -49.71 |
| tangible book value per share | -0.61 | -0.82 | 25.35 |
| shareholders equity per share | 1.6 | 3.18 | -49.71 |
| interest debt per share | 1.11 | 2.15 | -48.31 |
| market cap | 5401618.46 | 5251065.78 | 2.87 |
| enterprise value | 12515012.46 | 11134728.78 | 12.40 |
| pe ratio | -0.37 | -0.41 | 11.16 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -3.66 | -2.66 | -37.66 |
| pfcf ratio | -3.64 | -2.65 | -37.13 |
| pb ratio | 0.3 | 0.25 | 18.22 |
| ptb ratio | 0.3 | 0.25 | 18.22 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -5.63 | -6.01 | 6.39 |
| ev to operating cash flow | -8.48 | -5.64 | -50.42 |
| ev to free cash flow | -8.43 | -5.62 | -49.83 |
| earnings yield | -0.68 | -0.61 | -12.56 |
| free cash flow yield | -0.27 | -0.38 | 27.08 |
| debt to equity | 0.68 | 0.67 | 1.47 |
| debt to assets | 0.39 | 0.39 | 0.02 |
| net debt to ebitda | -3.2 | -3.18 | -0.69 |
| current ratio | 1.37 | 1.48 | -7.29 |
| interest coverage | -11.48 | -25.67 | 55.28 |
| income quality | 0.4 | 0.62 | -35.46 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.79 | 0.73 | 8.33 |
| capex to operating cash flow | -0.01 | -0.0 | -132.21 |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0.01 | 0.0 | 71.49 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 3.43 | 5.92 | -41.99 |
| roic | -0.1 | -0.09 | -13.33 |
| return on tangible assets | -0.57 | -0.34 | -69.91 |
| graham net net | -0.72 | -1.03 | 30.35 |
| working capital | 1518434 | 2728396 | -44.35 |
| tangible asset value | -6866034 | -5315782 | -29.16 |
| net current asset value | -7698326 | -6355516 | -21.13 |
| invested capital | 27055746 | 29447554 | -8.12 |
| average receivables | 4.5 | 2090.5 | -99.78 |
| average payables | 0 | 0.5 | -100.00 |
| average inventory | 163511.5 | 167988.5 | -2.67 |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 0 | NaN |
| days of inventory on hand | 26440.75 | 589.96 | 4381.81 |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0 | NaN |
| inventory turnover | 0.0 | 0.15 | -97.77 |
| roe | -0.21 | -0.15 | -33.07 |
| capex per share | 0.0 | 0.0 | 0.28 |
ROE: Return on Equity (ROE) decreased to -0.21 on 2024-09-30 Q3 from -0.15 on 2024-06-30 Q2, representing a change of -33.07%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -0.37 on 2024-09-30 Q3 from -0.41 on 2024-06-30 Q2, representing a change of 11.16%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 1.37 on 2024-09-30 Q3 from 1.48 on 2024-06-30 Q2, representing a change of -7.29%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.68 on 2024-09-30 Q3 from 0.67 on 2024-06-30 Q2, representing a change of 1.47%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-17 09:00:00
SAN DIEGO, CA / ACCESS Newswire / January 17, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), today announced that it had received written notification (the "Written Notification") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company is eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule"). As previously reported, on July 15, 2024, the Company received a deficiency letter from the Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to the Rule and the Company had been given 180 calendar days, or until January 13, 2025, to regain compliance with the Rule.
Sentiment: Positive
Publish Date: 2025-01-13 10:00:00
Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities.
Sentiment: Positive
Publish Date: 2024-12-18 12:05:00
The following CORRECTS and REPLACES the release that was issued earlier today: Updated partner for VOC detection platform development From giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies and strategic collaborations SAN DIEGO, CA / ACCESSWIRE / December 18, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA ® low-dose interferon therapeutics, is pleased to provide a letter to shareholders from its Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai.
Sentiment: Positive
Publish Date: 2024-12-18 08:00:00
From giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies and strategic collaborations SAN DIEGO, CA / ACCESSWIRE / December 18, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA ® low-dose interferon therapeutics, is pleased to provide a letter to shareholders from its Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai.
Sentiment: Positive
Publish Date: 2024-12-13 08:00:00
SAN DIEGO, CA / ACCESSWIRE / December 13, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced its participation in the Webull Corporate Connect Service (CCS). This initiative aims to further expand the Company's investor outreach and enhance transparency with its growing shareholder base.
Sentiment: Positive
Publish Date: 2024-12-04 08:00:00
SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that Water Tower Research has issued a report highlighting Ainos' strategic partnership with Taiwan Tanabe Seiyaku for manufacturing and marketing VELDONA®, a novel therapeutic candidate for primary Sjögren's syndrome, in Taiwan. The report underscores the significance of Ainos' efforts to out-license VELDONA®, starting with this key regional partnership, and sets the stage for future global expansion.
Sentiment: Positive
Publish Date: 2024-12-02 08:00:00
San Diego, California--(Newsfile Corp. - December 2, 2024) - Ainos, Inc. (NASDAQ: AIMD) (NASDAQ: AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today proudly announced the signing of a strategically significant Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation in Japan, brings extensive pharmaceutical development and manufacturing expertise to the partnership.
Sentiment: Positive
Publish Date: 2024-11-13 08:00:00
Taiwan regulatory approval for the trial expected in Q1 2025 Remains committed to a capital-efficient business strategy SAN DIEGO, CA / ACCESSWIRE / November 13, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report on the Company's obtainment of Institutional Review Board ("IRB") approval from the Shuang Ho Hospital (Taipei Medical University) to conduct the VELDONA® clinical study for primary Sjogren's syndrome, along with 3Q24 results and multiple other developments. The report said an approval from Taiwan's Food and Drug Administration (TFDA) for the study is expected in next quarter, with the trial set to start around April 2025 and completion in December 2026.
Sentiment: Positive
Publish Date: 2024-11-11 08:00:00
IRB approval on track as scheduled Next step is obtaining all regulatory approvals, followed by site initiation visit VELDONA significantly increases unstimulated whole salivary flow in prior Phase 3 studies SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it has received Institutional Review Board ("IRB") approval from Shuang Ho Hospital, affiliated with Taipei Medical University (IRB Approval No.: TMU-JIRB No.
Sentiment: Positive
Publish Date: 2024-11-08 08:00:00
SAN DIEGO, CA / ACCESSWIRE / November 8, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics, today announced it has filed complaints with NASDAQ MarketWatch and the U.S. Securities and Exchange Commission (SEC), due to concerns about unusual trading activity in its common stock, specifically large-volume sell orders. Ainos suspects that these trading activities may involve regulatory violations and urges the regulators to investigate thoroughly to uphold market fairness and protect stockholder interests.
Sentiment: Positive
Publish Date: 2024-11-06 16:30:00
Secured multi-regional patent assets, strengthening Ainos' AI Nose technology. Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections.
Sentiment: Positive
Publish Date: 2024-10-28 08:00:00
Strengthens AI Nose Gas Sensing Technology with Additional Exclusively Licensed Patents Secures Exclusive Rights to Breakthrough Nitrogen-Oxygen Separation Technology with Superior Energy Efficiency and Ultra-Low Carbon Emissions, Advancing Sustainable Medical Practices SAN DIEGO, CA / ACCESSWIRE / October 28, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it has secured exclusive licensing rights for an additional 28 multi-regional patent assets from its strategic shareholder and product co-developer, Taiwan Carbon Nano Technology Corporation ("TCNT"). These patents encompass innovations in AI Nose gas sensing technology and extend Ainos' technological capabilities with a groundbreaking nitrogen-oxygen separation technology targeting medical applications.
Sentiment: Positive
Publish Date: 2024-10-24 10:50:00
Prioritizing VELDONA®'s development for oral warts in HIV+ patients and Sjogren's syndrome Burgeoning pet care market also presents growth opportunities for VELDONA® SAN DIEGO, CA / ACCESSWIRE / October 24, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, shared promising clinical progress of VELDONA® and its growth opportunities alongside upcoming milestones in the Water Tower Research ("WTR") Small-Cap Spotlight podcast, signaling strong potential for both human and animal health markets. WTR has published a report recapping highlights from the podcast.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
